Abstract LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC)
Year: 2025
Type: conference-abstract
Source: Clinical Cancer Research
Authors: Mafalda Oliveira, Tomás Pascual, Kepa Amillano Parraga, Javier Salvador Bofill, Santiago González-Santiago, Clara Martínz Vila, Josefina Cruz, Xavier González-Farré, Elena Galve, Pilar Sánchez Henarejos, Juan Miguel Cejalvo, Maria-Eva Pérez-Lopez, Montse Muñoz, Serafin Morales, Alba González-Haba, Maria Borrell Puy, Encarnación González, Juan A. Guerra, Sergio Hoyos, Antonia Perelló, Pablo Tolosa Ortega, Juan De la Haba, Yenlik Zheteyava, David W. Sternberg, Fumitaka Suto, Esther Pang, Dalila Sellami, Rodrigo Sánchez-Bayona, Guillermo Villacampa, Samyukta Chillara, Mariana Paes Dias, Juan M. Ferrero-Cafiero, Aleix Prat
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4411286558